One plausible explanation is that higher phos is a surrogate for other components of CKD–MBD, such as low vitamin D or increased PTH and FGF23 levels, which are linked to lower Hb levels or resistance to EPO therapy32–36. This evidence concerns the gene PTH and Marchiafava-Bignami disease.